The American Society for Radiation Oncology (ASTRO) today expressed strong support for the nomination of radiation oncologist Stephen Hahn, MD, FASTRO, as Commissioner of the Food and Drug Administration (FDA). Dr. Hahn served on the ASTRO Board of Directors from 2014 to 2018.
Tag: FDA
KIDNEY HEALTH INITIATIVE LAUNCHES PROJECT TO MEASURE PATIENT PREFERENCES FOR NOVEL KIDNEY DEVICES
The US Food and Drug Administration (FDA) has awarded a contract to the Kidney Health Initiative (KHI) to study patient preferences for innovative renal replacement therapy (RRT) devices. The three-year project, “Building Capacity to Incorporate Patient Preferences into the Development of Innovative Alternatives to Renal Replacement Therapy” will capture patient preference and risk tolerance data from people with kidney failure to drive innovations in RRT.
How Oncologists Can Ethically Navigate the “Right-to-Try” Drug Law
The 2018 federal Right to Try Act allows patients with a life-threatening illness to be treated with drugs that have not yet been approved by the Food and Drug Administration (FDA). Many in the oncology community say Right to Try strips away important regulatory protections and view the move as a risky step bound to create ethical dilemmas for physicians whose goal is to guide patients toward safe and appropriate treatment decisions. Oncology is one field at the forefront of requests for unapproved drugs. An interdisciplinary team of bioethicists, oncologists, and lawyers from Penn Medicine and other institutions penned a commentary published online this week in the Journal of Clinical Oncology to offer recommendations to help oncologists navigate this new “Right to Try” world, while maintaining their ethical obligations to patients.
FDA approves ultra-low gossypol cottonseed for human, animal consumption
The U.S. Food and Drug Administration has given the green light to ultra-low gossypol cottonseed, ULGCS, to be utilized as human food and in animal feed, something Texas A&M AgriLife researchers have been working on for nearly 25 years.
Rutgers Dean Available to Speak on FDA’s Approval of Second Drug to Prevent HIV
New Brunswick, NJ – Rutgers School of Public Health dean and expert on HIV/AIDS is available to comment on the Food and Drug Administration’s approval of a new drug, Descovy, for the prevention of HIV in men and transgender women.…
Oncologists Respond Swiftly to FDA Safety Alerts, Penn Study Finds
Within six months of the FDA’s move to restrict the label of two immunotherapies, usage of those therapies among oncologists dropped by about 50 percent, according to a new study from researchers in the Abramson Cancer Center at the University of Pennsylvania.